论文部分内容阅读
目的 :观察基因 ras和 p16在肝癌组织中的表达 ,探讨其在肝癌术后复发及预后中的作用。方法 :应用免疫组化 S- P法 ,检测 5 3例手术切除肝癌组织和 12例正常肝组织的 ras和 p16表达及与肝癌临床病理指标、术后复发及预后的关系。结果 :(1) ras在肝癌和正常肝组织中的阳性表达率分别为 6 6 .0 %和 34.0 % ,ras表达与肿瘤大小、有无肝内转移密切相关 (P均 <0 .0 5 )。ras阳性、阴性表达病例 3年复发率分别为 6 8.8%、38.9% ,3年生存率分别为37.1%、6 6 .7% (P<0 .0 5 )。 (2 ) p16在肝癌和正常肝组织中的阳性表达率各为 4 7.2 %、10 0 .0 % ,p16表达与有无肝内转移、组织分化密切相关 (P均 <0 .0 5 )。 p16阳性、阴性表达病例 3年复发率分别为 4 8.0 %、6 7.9% ,其 3年生存率分别为 6 4 .0 %、32 .1% (P均 <0 .0 5 )。 (3) ras和 p16在肝癌中的表达密切相关 (P<0 .0 1) ,p16阳性 ras阴性与 p16阴性ras阳性表达病例 3年复发率分别为 35 .7%、79.2 % ,3年生存率分别为 71.4 %、2 9.2 % ,差异有极显著性 (P<0 .0 1)。结论 :联合检测 p16和 ras的表达可作为判断肝癌术后复发及预后的有效指标 ,多基因分析比单基因分析更有价值
Objective: To observe the expression of gene ras and p16 in hepatocellular carcinoma and to explore its role in the recurrence and prognosis of hepatocellular carcinoma. METHODS: Immunohistochemical S-P method was used to detect the expression of ras and p16 in 53 cases of hepatocellular carcinoma and 12 cases of normal liver tissue, and to explore the relationship between the expression of ras and p16 and clinicopathological parameters, postoperative recurrence and prognosis. Results: (1) The positive rates of ras in liver cancer and normal liver tissues were 66.0 % and 34.0 %, respectively. The expression of ras was closely related to tumor size and intrahepatic metastasis (P<0.05). . The recurrence rates of ras positive and negative expression cases were 6 8.8% and 38.9%, respectively. The three-year survival rates were 37.1% and 6 6.7%, respectively (P < 0.05). (2) The positive expression rates of p16 in liver cancer and normal liver tissues were 47.2% and 100.0%, respectively. The expression of p16 was closely related to whether there was intrahepatic metastasis and tissue differentiation (P < 0.05). The recurrence rates of p16-positive and negative-expressing cases at 3 years were 48.0 % and 6 7.9%, respectively, and the 3-year survival rates were 64.0% and 32.1%, respectively (P < 0.05). (3) The expression of ras and p16 in liver cancer was closely related (P<0.01). The recurrence rates of p16-positive ras-negative and p16-negative ras-positive cases were 35.7% and 79.2%, respectively. The rates were 71.4 % and 2 9.2 %, respectively, and the difference was extremely significant (P < 0.01). Conclusion : The combined detection of p16 and ras expressions can be used as an effective index to judge the recurrence and prognosis of liver cancer. Multigene analysis is more valuable than single gene analysis.